Nowadays, monoclonal antibodies to the “programmed cell death protein 1” (PD-1) or to its ligand “programmed death-ligand 1” (PD-L1) either as monotherapy or in combination with chemotherapy are the standard of care for the treatment of advanced NSCLC patients [6]. Here, PDCD1 is linked to non-small cell lung carcinoma.